NICE published a final recommendation for AbbVie and Boehringer Ingelheim’s Risankizumab today, completing fast-track process that sees the psoriasis treatment gain market access in record time. The drug is one of the first treatments to go through NICE’s fast-track appraisal system, which accelerates the review process, whilst also cutting the standard 90-day implementation period down
Regulatory Affairs SpecialistRegulatory ProfessionalsEurope, Belgium, Leuven
- FULL TIME
Associate Manager Regulatory AffairsRegulatory ProfessionalsBerkshire, UK
- FULL TIME
Associate Director Regulatory AffairsRegulatory ProfessionalsCambridgeshire, UK
- FULL TIME
Senior Project Manager – RegulatoryRegulatory ProfessionalsCambridgeshire, UK
- FULL TIME
Regulatory Professionals is one of the fastest growing global integrated regulatory outsourcing providers with a network of 20,000 pharmaceutical professionals globally. Working exclusively within the regulatory functions of Pharmaceutical, Biotechnology, Medical Device, Consumer health / OTC and Diagnostics industries.
Our integrated regulatory affairs recruitment team is there to support partner organisations of all sizes. Ranging for one regulatory consultant, to deliver a specialist project, to outsourcing functional regulatory teams of over 100+, Regulatory Professionals are able to offer global support partnered with expert local knowledge. Our capabilities also offer contract and permanent regulatory staffing services to allow a 360 degree service range for all aspects of regulatory delivery.
Our regulatory recruitment teams approach is tailored to meet the needs of our partners requirements allowing you to shift internal R&D focus to more strategic activities to improve lifecycle performance.
The benefits of Regulatory Professionals integrated teams are measured not just in the savings that could result in multi-mullion dollar cost reductions, but equally in understanding that delays in any part of the regulatory cycle affect the ability to give patients access to transformational products.
Our integrated teams support your product portfolio by giving you flexibility of resource at the peaks and troughs of the product life cycle, while ensuring you maintain control of strategic regulatory departments. This is supported by consistent, measurable and tracked metrics to maximise accountability.
To find out more about each of the regulatory areas we specialise in, take a look at the following regulatory recruitment services:
Our experienced specialist recruitment consultants are available to speak to you confidentially about our outsourcing regulatory affairs services. To find out more information or to discuss any of our regulatory vacancies, please call our specialist regulatory affairs recruitment team.
Contact us today to find out how we can progress your career to the next level
NICE has published its new draft recommendations on the use of cannabis-based medicinal products, following a comprehensive evaluation of their clinical and cost-effectiveness. The organisation says that the recommendation of fast-tracked guidance follows the re-classification of these products last year to allow specialist doctors to ‘prescribe them where the clinical needs of patients cannot be
EMA has decided on a positive opinion for a new combo of MSD’s cancer blockbuster, Keytruda (pembrolizumab) and Inlyta (axitinib). The organisation’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of the anti-PD-1 therapy and Inlyta combo, a tyrosine kinase inhibitor, for the first-line treatment of patients with advanced